DOTATATE PET for Meningioma Radiation Planning

NCT06937268 | Not Yet Recruiting

• 1 other identifier: H22-03733
• Study Type: interventional
• Target: 36
• Locations: 1 country
• Sites: 1

Brief Summary

68Ga-DOTATATE-based radionuclides are a novel modality in the diagnosis and treatment of central nervous system meningioma. DOTATATE is a ligand for the SSTR (somatostatin receptor), which is expressed in meningioma but not in normal brain or bone. It is also more effective than MRI in delineating tumor, which is the current imaging standard for assessing meningioma. For radiation planning, it can help to reduce the risk of geometrical miss, identify area that require dose-escalation, and reduce dose to normal tissue. The purpose of the study is to compare the radiation therapy (RT) contouring and planning for meningioma with and without the use of 68Ga-DOTATATE-PET

Conditions

Meningioma

Outcome Measures

Primary Outcomes (1)

• Target radiation volume

  The volume of gross total volume (GTV), clinical target volume (CTV), planned target volume (PTV) contours, and volume of dose exposure to normal brain tissue using standard imaging and DOTATE-PET scan

  2 years

Secondary Outcomes (7)

• Local control

  2 years

• Progression-free survival

  2 years

• Perceived usefulness by radiation oncologist

  2 years

• Adverse event

  2 years

• Rate of DOTATATE-scan completion

  2 years

Study Arms (1)

DOTATATE-PET scan

EXPERIMENTAL

Diagnostic Test: DOTATATE-PET scan

Interventions

DOTATATE-PET scan DIAGNOSTIC_TEST

DOTATATE tracer PET scan for meningioma

DOTATATE-PET scan

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years old
• Able and willing to comply with the study procedures
• Intact meningioma requiring definitive radiation
• Post-operative meningioma requiring adjuvant radiation
• No prior radiation therapy or medical therapy directed at the tumour

You may not qualify if:

• Breastfeeding or pregnancy
• Claustrophobia or inability to lie still in a supine position
• Unwillingness or inability to provide informed consent

Sponsors & Collaborators

• British Columbia Cancer Agency: lead

Study Sites (1)

BC Cancer - Vancouver

Vancouver, British Columbia, V5Z 4E6, Canada

Location

MeSH Terms

Conditions

Meningioma

Condition Hierarchy (Ancestors)

Neoplasms, Nerve Tissue; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Vascular Tissue; Meningeal Neoplasms; Central Nervous System Neoplasms; Nervous System Neoplasms; Neoplasms by Site; Nervous System Diseases

Central Study Contacts

Sandy Chang

CONTACT

6048776000; sandy.chang@bccancer.bc.ca

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 15, 2025
• First Posted: April 22, 2025
• Study Start: June 1, 2025
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2027
• Last Updated: April 22, 2025

Record last verified: 2025-04

Locations

CA (1)